FeRx begins magnetic drug-delivery trial:
This article was originally published in Clinica
FeRx has begun a clinical trial to investigate the use of its magnetic targeted carrier (MTC) drug-delivery technology for the treatment of metastatic liver cancer. The trial of the company's MTC-DOX product will assess the MTC microparticles as a means of delivering a widely-used anti-cancer drug, doxorubicin. MTC-DOX is already being tested in clinical trials of patients with primary liver cancers, says the San Diego, California company. MTC microparticles are composed of elemental iron and activated carbon and can be directed to specific sites in the body using an externally applied magnetic field.
You may also be interested in...
FDA action awaits Sun’s manufacturing facility in Halol after it failed to adequately address GMP deviations, though India’s top-ranked drug firm appears to have effectively lowered its dependence on the site that has had a patchy compliance run.
In a surprise to the market, Dr Reddy’s and Hikma have prevailed in challenging six method-of-use patents shielding Amarin’s Vascepa in the US, opening the door for a potential at-risk launch that would likely be challenged by the originator.
Duo will study up to four novel preclinical targets identified by Sitryx that may lead to potential new drugs for autoimmune diseases, which Lilly would then commercialize.